TYRA Stock Earnings Tyra Biosciences Beats EPS for Q2 2024
TYRA Stock | USD 16.19 0.04 0.25% |
About 66% of Tyra Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Tyra Biosciences suggests that many traders are alarmed. The current market sentiment, together with Tyra Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Tyra Biosciences stock news signals to limit their universe of possible portfolio assets.
Tyra |
TYRA stock results show that Tyra Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Read at investorplace.com
Tyra Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tyra Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tyra Biosciences Fundamental Analysis
We analyze Tyra Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tyra Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tyra Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Tyra Biosciences is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Tyra Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tyra Biosciences stock to make a market-neutral strategy. Peer analysis of Tyra Biosciences could also be used in its relative valuation, which is a method of valuing Tyra Biosciences by comparing valuation metrics with similar companies.
Peers
Tyra Biosciences Related Equities
DSGN | Design Therapeutics | 6.75 | ||||
XLO | Xilio Development | 5.56 | ||||
PHVS | Pharvaris | 5.21 | ||||
CCCC | C4 Therapeutics | 2.07 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
CNTB | Connect Biopharma | 0.96 | ||||
RAPT | RAPT Therapeutics | 0.84 | ||||
GLUE | Monte Rosa | 0.00 | ||||
MOLN | Molecular Partners | 0.00 | ||||
IPSC | Century Therapeutics | 0.11 | ||||
ERAS | Erasca | 0.54 | ||||
IKNA | Ikena Oncology | 0.66 | ||||
HOWL | Werewolf Therapeutics | 0.75 | ||||
STOK | Stoke Therapeutics | 1.06 | ||||
PMVP | Pmv Pharmaceuticals | 1.44 | ||||
EWTX | Edgewise Therapeutics | 1.72 | ||||
MLYS | Mineralys Therapeutics, | 2.74 |
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |